Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeted therapies: Combined lapatinib and paclitaxel in HER2-positive breast cancer.

Literature DB >> 19483734

Targeted therapies: Combined lapatinib and paclitaxel in HER2-positive breast cancer.

Abstract

A randomized phase III trial evaluated the effect of adding lapatinib to paclitaxel as first-line therapy for patients with metastatic breast cancer whose tumors were negative or untested for human epidermal growth factor receptor 2 (HER2) overexpression. Progression-free survival was prolonged significantly in patients with HER2-overexpressing tumors, which indicates that lapatinib exerts its main effects via the HER2 pathway.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2009 PMID： 19483734 DOI： 10.1038/nrclinonc.2009.68

Source DB: PubMed Journal: Nat Rev Clin Oncol ISSN： 1759-4774 Impact factor: 66.675

7 in total

1. Effects of paclitaxel, cyclophosphamide, ifosfamide, tamoxifen and cyclosporine on the metabolism of methoxymorpholinodoxorubicin in human liver microsomes.

Authors: Dominique Beulz-Riché; Jacques Robert; Christian Riché; Damrong Ratanasavanh
Journal: Cancer Chemother Pharmacol Date: 2002-01-30 Impact factor: 3.333

2. Global cancer statistics, 2002.

Authors: D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal: CA Cancer J Clin Date: 2005 Mar-Apr Impact factor: 508.702

Review 3. Targeting the EGFR pathway for cancer therapy.

Authors: James B Johnston; Sri Navaratnam; Marshall W Pitz; Jerry M Maniate; Emilia Wiechec; Heinrich Baust; Joel Gingerich; Georgios P Skliris; Leigh C Murphy; Marek Los
Journal: Curr Med Chem Date: 2006 Impact factor: 4.530

4. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.

Authors: Angelo Di Leo; Henry L Gomez; Zeba Aziz; Zanete Zvirbule; Jose Bines; Michael C Arbushites; Stephanie F Guerrera; Maria Koehler; Cristina Oliva; Steven H Stein; Lisa S Williams; Judy Dering; Richard S Finn; Michael F Press
Journal: J Clin Oncol Date: 2008-10-27 Impact factor: 44.544

5. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer.

Authors: Henry L Gomez; Dinesh C Doval; Miguel A Chavez; Peter C-S Ang; Zeba Aziz; Shona Nag; Christina Ng; Sandra X Franco; Louis W C Chow; Michael C Arbushites; Michelle A Casey; Mark S Berger; Steven H Stein; George W Sledge
Journal: J Clin Oncol Date: 2008-05-05 Impact factor: 44.544

Review 6. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer.

Authors: Quanri Jin; Francisco J Esteva
Journal: J Mammary Gland Biol Neoplasia Date: 2008-11-25 Impact factor: 2.673

7. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.

Authors: David Cameron; Michelle Casey; Michael Press; Deborah Lindquist; Tadeusz Pienkowski; C Gilles Romieu; Stephen Chan; Agnieszka Jagiello-Gruszfeld; Bella Kaufman; John Crown; Arlene Chan; Mario Campone; Patrice Viens; Neville Davidson; Vera Gorbounova; Johannes Isaac Raats; Dimosthenis Skarlos; Beth Newstat; Debasish Roychowdhury; Paolo Paoletti; Cristina Oliva; Stephen Rubin; Steven Stein; Charles E Geyer
Journal: Breast Cancer Res Treat Date: 2008-01-11 Impact factor: 4.872

7 in total

5 in total

5. Dual targeting micelles loaded with paclitaxel and lapatinib for combinational therapy of brain metastases from breast cancer.

Authors: Heng Lu; Tianran Chen; Yiran Wang; Yuwei He; Zhiqing Pang; Yajie Wang
Journal: Sci Rep Date: 2022-02-16 Impact factor: 4.379